Current Oncology Reports

, 9:9

The use of HER2 modulation in the adjuvant setting


DOI: 10.1007/BF02951420

Cite this article as:
Johnson, P.H. & Esteva, F.J. Curr Oncol Rep (2007) 9: 9. doi:10.1007/BF02951420


Amplification of theher-2/neu gene is associated with poor prognosis in patients with early-stage and metastatic breast cancer. Trastuzumab is a humanized monoclonal antibody directed against the HER2 protein, which is overexpressed in approximately 25% of patients with primary invasive breast cancer. Randomized phase III clinical trials showed that administration of trastuzumab in combination with chemotherapy or following chemotherapy significantly improves disease-free and overall survival rates in patients with early-stage HER2-positive breast cancer. The integration of trastuzumab in the adjuvant setting is changing the natural history of HER2-driven breast cancer from one of the worst subtypes to one that is highly curable with available therapy.

Copyright information

© Current Science Inc. 2007

Authors and Affiliations

  1. 1.Departments of Breast Medical Oncology and Molecular & Cellular OncologyUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA